Insilico Medicine executives to appear across five global AI and biopharma summits in one week

Insilico Medicine has announced that its executive leadership team will appear at five artificial intelligence and biopharma events across the Middle East and Asia in late October 2026. Between October 26 and October 30, company co-founder and president Alex Aliper, co-CEO and chief scientific officer Feng Ren, and global head of business development Jue Wang are scheduled at conferences in Dubai, Hong Kong, Seoul, Suzhou and Shenzhen, where they will deliver keynotes, join panel discussions and present technical sessions on generative AI foundation models, small molecule pipeline development and the commercialization of AI-designed therapeutics.

The schedule opens in Dubai, where Aliper has been invited to the Dubai AI Festival 2026 at the Dubai World Trade Centre on October 26 and 27. On the afternoon of October 26, from 14:10 to 14:30, he is scheduled to deliver a keynote titled “Generative AI for drug discovery and healthcare delivery” on the Innovation Stage. According to the announcement, his presentation will focus on the company’s real-world practice in applying generative AI foundation models across what it describes as the entire chain of target discovery, molecular design, clinical development and healthcare delivery. The company frames his participation as an opportunity to expand strategic collaboration with the Middle East’s AI innovation ecosystem, alongside international business leaders, regulatory authorities and investors.

The Dubai AI Festival is described in the announcement as one of the leading AI industry events in the Middle East by scale and influence. Directed by H.H. Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai and Minister of Defence, the festival is jointly initiated by the Dubai International Financial Centre and the Dubai AI Campus, and organized by Terrapinn as the flagship event of Dubai AI Week. The 2026 edition features a Plenary Stage and an Innovation Stage across eight core tracks, including AI for All, Global AI Governance, Future of Work, Infrastructure and Investment, and is expected to convene global AI unicorns, government entities, multinational corporations and venture capital firms, with the stated aim of moving artificial intelligence from concept toward deep industrial implementation.

On the same two days, October 26 and 27, co-CEO and chief scientific officer Feng Ren will be in Hong Kong at the 2026 Global Healthcare Innovation Summit, held at the Grand Hyatt Hong Kong. On the afternoon of October 26, from 14:00 to 14:30, Ren will join a panel discussion titled “AI Pharma at an Inflection Point: Technological Innovation and Industry Transformation.” The panel sits within a broader summit theme of “Reshaping Global Healthcare Asset Valuations,” and the announcement states that Ren will explore how generative AI is reshaping the end-to-end drug discovery pipeline across three dimensions: technology, commercialization and AI innovation. He is also expected to draw on the company’s experience since its listing on the Hong Kong Stock Exchange as an AI pharma company.

The Hong Kong summit is hosted by the GHIS International Healthcare Innovation Alliance and organized by MedTrend, running under the main theme “Healthcare Innovation and Capital Transactions from a Global Perspective.” Its program combines forums, enterprise roadshows and one-on-one business partnering across four frontier fields: biopharmaceuticals, medical devices, digital health and medical AI, and life sciences. Organizers expect more than 70 global industry leaders, over 50 investment firms and more than 100 international investors, with over 1,000 targeted business meetings planned.

The circuit then moves to Seoul, where Jue Wang, the company’s global head of business development, will attend BioPlus-Interphex Korea 2026 at COEX from October 28 to 30. On the morning of October 30 at 11:50, she is scheduled to deliver a keynote presentation at a specialized session titled “We All Have AI. Now What?: Building Real Value in AI Drug Discovery.” Drawing on the company’s global track record in out-licensing, co-development and R&D partnerships, Wang is expected to discuss critical factors for scaling AI-driven drug discovery from concept into high-volume outputs, addressing the paradigm shift the session describes from merely having AI to maximizing its value.

Insilico Medicine will also maintain a commercial presence at the Seoul event, showcasing its solutions at Booth BF02. Its business development team plans to engage global partners on developments in AI drug discovery, display applications of generative AI across the entire drug lifecycle, and pursue what the company describes as multi-dimensional strategic partnerships. BioPlus-Interphex Korea is the flagship biopharma industry event hosted by the Korea Biotechnology Industry Organization and organized by RX Korea, uniting Korea’s BIOPLUS event with the global INTERPHEX exhibition brand, which has spanned more than 45 years across New York, Tokyo and beyond. The 2026 edition is expected to draw over 300 exhibitors from more than 25 countries, over 10,000 professional visitors, more than 36 thematic sessions and in excess of 500 business partnering meetings, covering the full value chain from drug discovery and development to biomanufacturing and packaging innovation.

On October 29, Ren is scheduled in Suzhou, China, at the 6th SAPA-China 2026 Healthcare Industry Conference at the Suzhou Shishan International Conference Center, where he will deliver two presentations illustrating the company’s journey from what the announcement calls “hardcore technology” to commercialization and capital markets. From 13:30 to 13:50, he will present “AI-Driven Small Molecule R&D from Demo to Pipeline: Target Identification, Molecule Generation, and Experimental Closed-Loop,” detailing the real-world application of the company’s Pharma.AI platform across small molecule research and development and the logic of generative AI in supporting preclinical and clinical pipeline development. Later, from 14:55 to 15:20, he will speak at the Investment, Financing and Entrepreneurship Forum on “IPO Fundraising Journey and BD Breakthroughs Amid the Capital Winter,” drawing on the company’s listing on the Main Board of the Hong Kong Stock Exchange in late 2025 to analyze financing strategies and business development licensing tactics under challenging market conditions.

The SAPA-China conference, hosted by the Sino-American Pharmaceutical Professionals Association and co-organized by the Suzhou Xushuguan Economic and Technological Development Zone Management Committee, runs from October 29 to 30 with one main plenary forum, 14 specialized venues and 42 parallel sessions. Its core tracks include small and large molecules, cell and gene therapy, nucleic acid drugs, AI pharma, clinical research, and investment and financing. Organizers anticipate more than 8,000 industry delegates and over 400 experts, positioning the event as one of China’s flagship annual pharmaceutical gatherings spanning source innovation through industrial application.

The final stop is Shenzhen, where Aliper will attend the 2026 Tencent Global Digital Ecosystem Summit at the Shenzhen World Exhibition and Convention Center on October 29 and 30. On the morning of October 30 at 09:55, he will deliver a speech titled “Cutting-Edge AI for Drug Discovery and Longevity Research: MMAI Gym and SOTA Models” at the Life Sciences Session. The announcement states that Aliper will present the company’s latest work with MMAI Gym for Science, a training framework used to build state-of-the-art expert models in chemistry and biology that the company says achieves state-of-the-art performance across more than 50 benchmark tasks. According to the company, these capabilities are intended to drive scalable innovation, enable the discovery of novel molecular entities and support diversification into broad indications. The Tencent summit, Tencent’s premier annual event for its industrial internet sector, has been held for eight consecutive editions since 2019 and showcases blueprints for cloud, AI, big data and security technologies alongside the company’s research achievements and industry solutions. Insilico Medicine, listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025 under the stock code 03696.HK, describes itself as integrating AI and automation technologies to accelerate drug discovery in fibrosis, oncology, immunology, pain, and obesity and metabolic disorders, and extends its Pharma.AI platform to industries including advanced materials, agriculture, nutritional products and veterinary medicine. The scientific and business claims presented at all five events remain those stated by the company in the announcement.

Subject of Research: Insilico Medicine executives' scheduled appearances at five global AI and biopharma conferences in October 2026

Article Title: Weekly丨Insilico Medicine executive leadership team to feature simultaneously across multiple global AI and biopharma innovation summits

Article References: Weekly丨Insilico Medicine executive leadership team to feature simultaneously across multiple global AI and biopharma innovation summits. Original publication (Bibliographic details unavailable.)

Image Credits: AI Generated

DOI: Not provided

Keywords: Insilico Medicine, generative AI, drug discovery, Dubai AI Festival, GHIS 2026, BioPlus-Interphex Korea, SAPA-China, Tencent Global Digital Ecosystem Summit, MMAI Gym, Pharma.AI, biopharma, Hong Kong Stock Exchange